Regulatory and Safety Aspects of Cell and Gene Therapy


Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.


  • Guidelines of cell therapy
  • safety precautions

Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

August 25-25, 2022

7th International Conference on Molecular Medicine and Diagnostics

Singapore City, Singapore
September 19-20, 2022

International Summit on Genomics and Proteomics

Dublin, Ireland
September 19-20, 2022

15th World Congress on Stem Cell Research

Dublin, Ireland
October 17-18, 2022

21st International Conference on Structural Biology

Barcelona, Spain
November 21-22, 2022

4th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada

Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in